Toll Like Receptor 4 - Pipeline Review, H2 2019
Toll Like Receptor 4 - Pipeline Review, H2 2019
SUMMARY
Toll Like Receptor 4 (hToll or CD284 or TLR4) - Toll-like receptor 4 is a protein encoded by the TLR4 gene. This receptor is mostly expressed in placenta, and in myelomonocytic subpopulation of the leukocytes. It is involved in LPS-independent inflammatory responses triggered by free fatty acids, such as palmitate, and Ni2+. It responses are triggered by Ni2+ require non-conserved. In complex with TLR6 promotes sterile inflammation in monocytes in response to oxidized low-density lipoprotein (oxLDL).
Toll Like Receptor 4 (hToll or CD284 or TLR4) pipeline Target constitutes close to 41 molecules. Out of which approximately 32 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 9, 3, 13 and 5 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 7 and 2 molecules, respectively. Report covers products from therapy areas Oncology, Gastrointestinal, Infectious Disease, Immunology, Cardiovascular, Central Nervous System, Respiratory, Genito Urinary System And Sex Hormones, Dermatology, Ear Nose Throat Disorders, Musculoskeletal Disorders, Ophthalmology, Other Diseases and Undisclosed which include indications Non-Alcoholic Steatohepatitis (NASH), Autoimmune Hepatitis, Non Alcoholic Fatty Liver Disease (NAFLD), Inflammation, Solid Tumor, Atherosclerosis, Chronic Liver Disease, Dengue Fever, Kidney Fibrosis, Liver Fibrosis, Pain, Rheumatoid Arthritis, Sepsis, Acute Ischemic Stroke, Acute Liver Failure, Acute Lung Injury, Alzheimer's Disease, Atopic Dermatitis (Atopic Eczema), Autoimmune Disorders, Bacterial Sepsis, Breast Cancer, Chronic Asthma, Chronic Obstructive Pulmonary Disease (COPD), Complicated Intra-Abdominal Infections, Crohn's Disease (Regional Enteritis), Cutaneous T-Cell Lymphoma, Cyst, Diffuse Large B-Cell Lymphoma, Drug Addiction, Ebolavirus Infections (Ebola Hemorrhagic Fever), Endotoxemia, Escherichia coli Infections, Follicular Lymphoma, Head And Neck Cancer Squamous Cell Carcinoma, Hearing Disorders, Hepatic Injury, Hypopharyngeal Cancer, Inflammatory Bowel Disease, Keratoconjunctivitis Sicca (Dry Eye), Laryngeal Cancer, Low Back Pain, Lung Cancer, Marburgvirus Infections (Marburg Hemorrhagic Fever), Marginal Zone B-cell Lymphoma, Melanoma, Merkel Cell Carcinoma, Metastatic Melanoma, Migraine, Necrotizing Enterocolitis, Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer), Oral Cavity (Mouth) Cancer, Oropharyngeal Cancer, Osteoarthritis, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Pseudomonas aeruginosa Infections, Pulmonary Edema, Pulmonary Inflammation, Rosacea, Soft Tissue Sarcoma and Unspecified Rare Disease.
The latest report Toll Like Receptor 4 - Pipeline Review, H2 2019, outlays comprehensive information on the Toll Like Receptor 4 (hToll or CD284 or TLR4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Toll Like Receptor 4 (hToll or CD284 or TLR4) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Toll Like Receptor 4 (hToll or CD284 or TLR4) - Toll-like receptor 4 is a protein encoded by the TLR4 gene. This receptor is mostly expressed in placenta, and in myelomonocytic subpopulation of the leukocytes. It is involved in LPS-independent inflammatory responses triggered by free fatty acids, such as palmitate, and Ni2+. It responses are triggered by Ni2+ require non-conserved. In complex with TLR6 promotes sterile inflammation in monocytes in response to oxidized low-density lipoprotein (oxLDL).
Toll Like Receptor 4 (hToll or CD284 or TLR4) pipeline Target constitutes close to 41 molecules. Out of which approximately 32 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 9, 3, 13 and 5 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 7 and 2 molecules, respectively. Report covers products from therapy areas Oncology, Gastrointestinal, Infectious Disease, Immunology, Cardiovascular, Central Nervous System, Respiratory, Genito Urinary System And Sex Hormones, Dermatology, Ear Nose Throat Disorders, Musculoskeletal Disorders, Ophthalmology, Other Diseases and Undisclosed which include indications Non-Alcoholic Steatohepatitis (NASH), Autoimmune Hepatitis, Non Alcoholic Fatty Liver Disease (NAFLD), Inflammation, Solid Tumor, Atherosclerosis, Chronic Liver Disease, Dengue Fever, Kidney Fibrosis, Liver Fibrosis, Pain, Rheumatoid Arthritis, Sepsis, Acute Ischemic Stroke, Acute Liver Failure, Acute Lung Injury, Alzheimer's Disease, Atopic Dermatitis (Atopic Eczema), Autoimmune Disorders, Bacterial Sepsis, Breast Cancer, Chronic Asthma, Chronic Obstructive Pulmonary Disease (COPD), Complicated Intra-Abdominal Infections, Crohn's Disease (Regional Enteritis), Cutaneous T-Cell Lymphoma, Cyst, Diffuse Large B-Cell Lymphoma, Drug Addiction, Ebolavirus Infections (Ebola Hemorrhagic Fever), Endotoxemia, Escherichia coli Infections, Follicular Lymphoma, Head And Neck Cancer Squamous Cell Carcinoma, Hearing Disorders, Hepatic Injury, Hypopharyngeal Cancer, Inflammatory Bowel Disease, Keratoconjunctivitis Sicca (Dry Eye), Laryngeal Cancer, Low Back Pain, Lung Cancer, Marburgvirus Infections (Marburg Hemorrhagic Fever), Marginal Zone B-cell Lymphoma, Melanoma, Merkel Cell Carcinoma, Metastatic Melanoma, Migraine, Necrotizing Enterocolitis, Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer), Oral Cavity (Mouth) Cancer, Oropharyngeal Cancer, Osteoarthritis, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Pseudomonas aeruginosa Infections, Pulmonary Edema, Pulmonary Inflammation, Rosacea, Soft Tissue Sarcoma and Unspecified Rare Disease.
The latest report Toll Like Receptor 4 - Pipeline Review, H2 2019, outlays comprehensive information on the Toll Like Receptor 4 (hToll or CD284 or TLR4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Toll Like Receptor 4 (hToll or CD284 or TLR4) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Toll Like Receptor 4 (hToll or CD284 or TLR4)
- The report reviews Toll Like Receptor 4 (hToll or CD284 or TLR4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Toll Like Receptor 4 (hToll or CD284 or TLR4) targeted therapeutics and enlists all their major and minor projects
- The report assesses Toll Like Receptor 4 (hToll or CD284 or TLR4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Toll Like Receptor 4 (hToll or CD284 or TLR4) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Toll Like Receptor 4 (hToll or CD284 or TLR4)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Toll Like Receptor 4 (hToll or CD284 or TLR4) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Toll Like Receptor 4 (hToll or CD284 or TLR4) - Overview
Toll Like Receptor 4 (hToll or CD284 or TLR4) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Toll Like Receptor 4 (hToll or CD284 or TLR4) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Toll Like Receptor 4 (hToll or CD284 or TLR4) - Companies Involved in Therapeutics Development
AptaTargets SL
ArTara Therapeutics Inc
Batu Biologics Inc
Cyxone AB
Eisai Co Ltd
eTheRNA Immunotherapies NV
EyeGene Inc
GigaGen Inc
GlaxoSmithKline Plc
Immunovo BV
Merck & Co Inc
NovImmune SA
TaiwanJ Pharmaceuticals Co Ltd
Takeda Pharmaceutical Co Ltd
Vascular Biogenics Ltd
Toll Like Receptor 4 (hToll or CD284 or TLR4) - Drug Profiles
(clonidine + naltrexone) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ALD-046 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ApTOLL - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AyuV-25 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Biologic to Agonize TLR4 for Drug Addiction - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Biologics to Antagonize TLR4 for Dengue Fever - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
C-34 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CIA-05 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DMT-210 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ECF-843 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ECI-006 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
eritoran tetrasodium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
G-100 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GBK-233 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Inhibit TLR4 for Acute Pain and Chronic Pain - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GSK-1795091 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
hp-91 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ISAS-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies to Agonize TLR4 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
nalmefene - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
naltrexone hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
naltrexone hydrochloride CR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NI-0101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
P-13 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
P-16 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
P-7 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
P-MAPA - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PEPA-10 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rabeximodum - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
resatorvid - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize TLR4 for Gastrointestinal Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize TLR2 and TLR4 for Pulmonary Edema, Inflammation and Sepsis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize TLR4 for Acute Lung Injury and Bacterial Sepsis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize TLR4 for Chronic Obstructive Pulmonary Disease, Chronic Asthma and Alzheimer’s Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize TLR4 for Dengue Fever - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptide to Antagonize TLR4 for Sepsis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptide to target TLR-4 for Oncology, Inflammation and Infectious Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TARA-002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TJC-0133 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VB-201 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VB-703 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Toll Like Receptor 4 (hToll or CD284 or TLR4) - Dormant Products
Toll Like Receptor 4 (hToll or CD284 or TLR4) - Discontinued Products
Toll Like Receptor 4 (hToll or CD284 or TLR4) - Product Development Milestones
Featured News & Press Releases
Appendix
Global Markets Direct Report Coverage
Toll Like Receptor 4 (hToll or CD284 or TLR4) - Overview
Toll Like Receptor 4 (hToll or CD284 or TLR4) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Toll Like Receptor 4 (hToll or CD284 or TLR4) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Toll Like Receptor 4 (hToll or CD284 or TLR4) - Companies Involved in Therapeutics Development
AptaTargets SL
ArTara Therapeutics Inc
Batu Biologics Inc
Cyxone AB
Eisai Co Ltd
eTheRNA Immunotherapies NV
EyeGene Inc
GigaGen Inc
GlaxoSmithKline Plc
Immunovo BV
Merck & Co Inc
NovImmune SA
TaiwanJ Pharmaceuticals Co Ltd
Takeda Pharmaceutical Co Ltd
Vascular Biogenics Ltd
Toll Like Receptor 4 (hToll or CD284 or TLR4) - Drug Profiles
(clonidine + naltrexone) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ALD-046 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ApTOLL - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AyuV-25 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Biologic to Agonize TLR4 for Drug Addiction - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Biologics to Antagonize TLR4 for Dengue Fever - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
C-34 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CIA-05 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DMT-210 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ECF-843 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ECI-006 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
eritoran tetrasodium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
G-100 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GBK-233 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Inhibit TLR4 for Acute Pain and Chronic Pain - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GSK-1795091 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
hp-91 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ISAS-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies to Agonize TLR4 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
nalmefene - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
naltrexone hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
naltrexone hydrochloride CR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NI-0101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
P-13 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
P-16 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
P-7 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
P-MAPA - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PEPA-10 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rabeximodum - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
resatorvid - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize TLR4 for Gastrointestinal Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize TLR2 and TLR4 for Pulmonary Edema, Inflammation and Sepsis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize TLR4 for Acute Lung Injury and Bacterial Sepsis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize TLR4 for Chronic Obstructive Pulmonary Disease, Chronic Asthma and Alzheimer’s Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize TLR4 for Dengue Fever - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptide to Antagonize TLR4 for Sepsis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptide to target TLR-4 for Oncology, Inflammation and Infectious Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TARA-002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TJC-0133 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VB-201 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VB-703 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Toll Like Receptor 4 (hToll or CD284 or TLR4) - Dormant Products
Toll Like Receptor 4 (hToll or CD284 or TLR4) - Discontinued Products
Toll Like Receptor 4 (hToll or CD284 or TLR4) - Product Development Milestones
Featured News & Press Releases
Appendix
LIST OF TABLES
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indications, H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..2), H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Products under Development by Companies, H2 2019 (Contd..3), H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by AptaTargets SL, H2 2019
Pipeline by ArTara Therapeutics Inc, H2 2019
Pipeline by Batu Biologics Inc, H2 2019
Pipeline by Cyxone AB, H2 2019
Pipeline by Eisai Co Ltd, H2 2019
Pipeline by eTheRNA Immunotherapies NV, H2 2019
Pipeline by EyeGene Inc, H2 2019
Pipeline by GigaGen Inc, H2 2019
Pipeline by GlaxoSmithKline Plc, H2 2019
Pipeline by Immunovo BV, H2 2019
Pipeline by Merck & Co Inc, H2 2019
Pipeline by NovImmune SA, H2 2019
Pipeline by TaiwanJ Pharmaceuticals Co Ltd, H2 2019
Pipeline by Takeda Pharmaceutical Co Ltd, H2 2019
Pipeline by Vascular Biogenics Ltd, H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019
Dormant Products, H2 2019 (Contd..2), H2 2019
Dormant Products, H2 2019 (Contd..3), H2 2019
Dormant Products, H2 2019 (Contd..4), H2 2019
Discontinued Products, H2 2019
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indications, H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..2), H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Products under Development by Companies, H2 2019 (Contd..3), H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by AptaTargets SL, H2 2019
Pipeline by ArTara Therapeutics Inc, H2 2019
Pipeline by Batu Biologics Inc, H2 2019
Pipeline by Cyxone AB, H2 2019
Pipeline by Eisai Co Ltd, H2 2019
Pipeline by eTheRNA Immunotherapies NV, H2 2019
Pipeline by EyeGene Inc, H2 2019
Pipeline by GigaGen Inc, H2 2019
Pipeline by GlaxoSmithKline Plc, H2 2019
Pipeline by Immunovo BV, H2 2019
Pipeline by Merck & Co Inc, H2 2019
Pipeline by NovImmune SA, H2 2019
Pipeline by TaiwanJ Pharmaceuticals Co Ltd, H2 2019
Pipeline by Takeda Pharmaceutical Co Ltd, H2 2019
Pipeline by Vascular Biogenics Ltd, H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019
Dormant Products, H2 2019 (Contd..2), H2 2019
Dormant Products, H2 2019 (Contd..3), H2 2019
Dormant Products, H2 2019 (Contd..4), H2 2019
Discontinued Products, H2 2019
LIST OF FIGURES
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Mechanism of Actions, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019
COMPANIES MENTIONED
AptaTargets SL
ArTara Therapeutics Inc
Batu Biologics Inc
Cyxone AB
Eisai Co Ltd
eTheRNA Immunotherapies NV
EyeGene Inc
GigaGen Inc
GlaxoSmithKline Plc
Immunovo BV
Merck & Co Inc
NovImmune SA
TaiwanJ Pharmaceuticals Co Ltd
Takeda Pharmaceutical Co Ltd
Vascular Biogenics Ltd
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Mechanism of Actions, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019
COMPANIES MENTIONED
AptaTargets SL
ArTara Therapeutics Inc
Batu Biologics Inc
Cyxone AB
Eisai Co Ltd
eTheRNA Immunotherapies NV
EyeGene Inc
GigaGen Inc
GlaxoSmithKline Plc
Immunovo BV
Merck & Co Inc
NovImmune SA
TaiwanJ Pharmaceuticals Co Ltd
Takeda Pharmaceutical Co Ltd
Vascular Biogenics Ltd
